Figure 1
![Figure 1. cFIX-R338L antigen and activity levels over time in HB dogs treated with AAV6-cFIX-R338L. Three adult male HB dogs (M55 [A], M59 [B], and N07 [C]) were administered 2.5-3 × 1012 vg/kg of AAV6-cFIX-R338L by peripheral transvenular delivery to the skeletal muscle. cFIX antigen levels were measured over time by ELISA (□), and cFIX activity levels were measured by activated partial thromboplastin time (●). Black arrows indicate weekly challenges with pooled normal canine plasma (100 mL). (D) PBMCs collected from M59 and N07 after the fourth challenge were subjected to IFN-γ ELISpot analysis after stimulation with AAV6 capsid, cFIX protein, or overlapping peptides spanning the 338 region (RATCLR/LSTKFTIYNM, LKVPVDRATCLR/LST).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/120/23/10.1182_blood-2012-06-440123/4/zh89991297480001.jpeg?Expires=1722791678&Signature=QAgdTi4PMcaZvGeW1fm-MwoyE9FLXnAhcr2V1-Q4xUZl5yIYBUbP1QL6YPUwy-o--tf-Q59xa1706rZ0Ou5caq0WgZFVJaZNaGcX9xgwgca3dGzW61VE4Os08FY365mKRsjrcBPlMXuutMEIfa7TCTfo60G2vu2cQUmdWhc2~9Zbh-v2NOGZZbakUhZV6s2y~tAIM1W32g6pmsdJ1ucH5L5a9bFnCMPEMw~AmuwaV7NIUuT~SppVoBgYQBDBCu8e2xpx1eG0HLYM0KnyBst4SnVhHWDKJdoM3H9v3aLW4t1mloX3fMu7ZfjXFUF3upunA31O1A4ZeleCIe2RZGR4Qw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
cFIX-R338L antigen and activity levels over time in HB dogs treated with AAV6-cFIX-R338L. Three adult male HB dogs (M55 [A], M59 [B], and N07 [C]) were administered 2.5-3 × 1012 vg/kg of AAV6-cFIX-R338L by peripheral transvenular delivery to the skeletal muscle. cFIX antigen levels were measured over time by ELISA (□), and cFIX activity levels were measured by activated partial thromboplastin time (●). Black arrows indicate weekly challenges with pooled normal canine plasma (100 mL). (D) PBMCs collected from M59 and N07 after the fourth challenge were subjected to IFN-γ ELISpot analysis after stimulation with AAV6 capsid, cFIX protein, or overlapping peptides spanning the 338 region (RATCLR/LSTKFTIYNM, LKVPVDRATCLR/LST).
